{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "4cc16346",
   "metadata": {},
   "source": [
    "# Breast Cancer Survival Analysis: Study Protocol\n",
    "\n",
    "## 1. Study Objective\n",
    "\n",
    "**Primary Objective**: \n",
    "Develop and compare prognostic models for breast cancer survival using \n",
    "clinical variables and gene expression data.\n",
    "\n",
    "**Secondary Objectives**:\n",
    "- Identify gene expression signatures associated with survival outcomes\n",
    "- Compare predictive performance of traditional statistical vs. regularized \n",
    "  machine learning approaches\n",
    "- Demonstrate methods applicable to precision oncology real-world evidence\n",
    "\n",
    "---\n",
    "\n",
    "## 2. Data Source\n",
    "\n",
    "**Dataset**: METABRIC Breast Cancer Gene Expression and Clinical Data\n",
    "\n",
    "**Source**: Kaggle (https://www.kaggle.com/datasets/raghadalharbi/breast-cancer-gene-expression-profiles-metabric)\n",
    "\n",
    "**Expected Sample**:\n",
    "- 1,904 patients\n",
    "- Metastatic/advanced breast cancer\n",
    "- Survival outcomes, genetic expression variables, clinical variables\n",
    "\n",
    "---\n",
    "\n",
    "## 3. Study Population\n",
    "\n",
    "**Inclusion Criteria**:\n",
    "- Patients with complete survival data (time and event status)\n",
    "- Survival time > 0 months\n",
    "- At least one clinical covariate available\n",
    "\n",
    "**Exclusion Criteria**:\n",
    "- Missing survival time or event indicator\n",
    "\n",
    "**Handling Missing Data**:\n",
    "- Clinical variables: Complete case analysis for Cox models\n",
    "- Gene expression: Complete case analysis or imputation if missingness exceeds 10% but is lower than 30%\n",
    "- Sensitivity analysis: Compare complete cases vs. imputed\n",
    "\n",
    "---\n",
    "\n",
    "## 4. Study Variables\n",
    "\n",
    "### **Outcome Variable**\n",
    "- **Primary**: Overall survival\n",
    "  - Time: Months from diagnosis to death or last follow-up\n",
    "  - Event: Death (1) vs. censored (0)\n",
    "\n",
    "### **Clinical Covariates** (pre-specified)\n",
    "- Age at diagnosis (continuous)\n",
    "- Tumor stage (categorical: I, II, III, IV or T1-T4)\n",
    "- ER status (positive/negative)\n",
    "- PR status (positive/negative)  \n",
    "- HER2 status (positive/negative)\n",
    "- Tumor grade (1/2/3)\n",
    "\n",
    "### **Genomic Features**\n",
    "- Specific genes of interest (ESR1, ERBB2, TP53, PIK3CA)\n",
    "\n",
    "---\n",
    "\n",
    "## 5. Statistical Analysis Plan\n",
    "\n",
    "### **5.1 Kaplan-Meier Analysis**\n",
    "- Overall survival curve with 95% CI, overall and stratified (see below for stratifications)\n",
    "- Median survival time, overall and stratified\n",
    "- 5-year survival probability, overall and stratified\n",
    "\n",
    "**Stratified Analysis** (pre-specified):\n",
    "- By ER status\n",
    "- By tumor stage\n",
    "- By HER2 status (if available)\n",
    "\n",
    "**Statistical Test**: Log-rank test for differences in KM (α = 0.05)\n",
    "\n",
    "### **5.2 Cox Proportional Hazards Models**\n",
    "\n",
    "**Model 1: Clinical Variables Only**\n",
    "- Covariates: Age, stage, ER status, PR status, HER2 status, grade\n",
    "- Check proportional hazards assumption (Schoenfeld residuals at p > 0.05)\n",
    "- Report: Hazard ratios (HR), 95% CI, p-values\n",
    "- Performance: Concordance index (C-index)\n",
    "\n",
    "**Model 2: Gene Expression (LASSO Regularization)**\n",
    "- Method: CoxNet with LASSO penalty (L1_ratio = 1.0)\n",
    "- Cross-validation: 5-fold CV to select optimal alpha\n",
    "- Feature selection: Genes with non-zero coefficients\n",
    "- Performance: C-index\n",
    "\n",
    "**Model 3: Combined Clinical + Selected Genes**\n",
    "- Include clinical variables + genes selected by LASSO\n",
    "- Performance: C-index\n",
    "- Comparison: Bootstrap 95% CI for C-index difference\n",
    "\n",
    "### **5.3 Model Validation**\n",
    "- **Internal validation**: Train/test split (70/30)\n",
    "  - Random seed for reproducibility\n",
    "  - Stratify by event status\n",
    "- **Calibration**: Compare predicted vs. observed survival\n",
    "- **Discrimination**: C-index on test set\n",
    "\n",
    "### **5.4 Sensitivity Analyses**\n",
    "- Complete case vs. imputed cases for gene expression\n",
    "- Alternative regularization: Elastic Net (L1_ratio = 0.5)\n",
    "- Time-varying effects for variables violating PH assumption \n",
    "\n",
    "---\n",
    "\n",
    "## 6. Statistical Considerations\n",
    "\n",
    "**Sample Size**: \n",
    "- Satisfies ≥10 events per predictor variable\n",
    "- For high-dimensional genomic data, use LASSO or ElasticNet to prevent overfitting\n",
    "\n",
    "**Multiple Testing**:\n",
    "- For gene expression: Control via LASSO or ElasticNet\n",
    "- For clinical variables: No adjustment\n",
    "\n",
    "**Missing Data**:\n",
    "- Report % missing for all variables\n",
    "- Clinical: Complete case analysis (assume MCAR)\n",
    "- Genes: Median imputation if missingness <10%; consider alternative approaches if missingness exceeds 10%\n",
    "\n",
    "**Significance Level**: α = 0.05 (two-sided)\n",
    "\n",
    "---\n",
    "\n",
    "## 7. Performance Metrics\n",
    "\n",
    "| Metric | Definition | Target |\n",
    "|--------|------------|--------|\n",
    "| C-index | Concordance index (discrimination) | > 0.70 |\n",
    "| Median survival | Time when S(t) = 0.50 | Report with 95% CI |\n",
    "| 5-year survival | Probability at 60 months | Report with 95% CI |\n",
    "| Model comparison | ΔC-index (genomic vs. clinical) | > 0.05 meaningful |\n",
    "\n",
    "---\n",
    "\n",
    "## 8. Software & Reproducibility\n",
    "\n",
    "**Environment**:\n",
    "- Python 3.11\n",
    "- Key packages: pandas, lifelines, scikit-survival, matplotlib, seaborn\n",
    "- Random seed: 28 (all analyses)\n",
    "\n",
    "**Code Structure**:\n",
    "- `breast_cancer_survival_analysis.ipynb`: Complete analysis workflow including data loading, cleaning, exploratory analysis, Cox regression (clinical variables), regularized Cox (genomic features), and model comparison\n",
    "- `Metastatic_Breast_Cancer_Survival_Prediction_Protocol.md`: Pre-specified study protocol and statistical analysis plan\n",
    "- `README.md`: Project overview and key findings\n",
    "---\n",
    "\n",
    "## 9. Deliverables\n",
    "\n",
    "1. **Analysis Code**: Jupyter notebooks with documented workflow\n",
    "2. **Results Summary**: Markdown file with key findings, including visualizations/KM curves, model results and interpretation, model comparison\n",
    "5. **GitHub Repository**: Public portfolio project\n",
    "\n",
    "---\n",
    "\n",
    "## 10. Limitations (Pre-Specified)\n",
    "\n",
    "- **Retrospective observational data**: Cannot establish causality\n",
    "- **Selection bias**: Dataset may not represent all breast cancer patients\n",
    "- **Generalizability**: Single dataset, may not generalize to other populations\n",
    "- **Unmeasured confounding**: Clinical variables may not capture all prognostic factors\n",
    "- **High-dimensionality**: More genes than samples, requires regularization\n",
    "- **No external validation**: Limited to internal train/test split\n",
    "\n",
    "---\n",
    "\n",
    "## 11. Interpretation Framework\n",
    "\n",
    "**Model fitting success**:\n",
    "- Clinical model C-index > 0.65 (reasonable discrimination)\n",
    "- Genomic features improve C-index by ≥ 0.05\n",
    "- Selected genes have biological plausibility (ER, HER2, proliferation genes)\n",
    "- Results align with known breast cancer biology\n",
    "\n",
    "**Red flags to investigate**:\n",
    "- C-index < 0.60 (poor discrimination)\n",
    "- Proportional hazards violations for key variables\n",
    "- Selected genes have no known cancer association (overfitting)\n",
    "- Large train/test performance gap (overfitting)\n",
    "\n",
    "---\n",
    "\n",
    "## Version History\n",
    "- v1.0 (2025-01-30): Initial analysis plan\n",
    "- Updates will be documented with rationale"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9f81badb",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "7f5d95b8",
   "metadata": {},
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
